InnovAAVector is a CDMO specializing in the design, development, and GMP production of adeno-associated viral (AAV) vectors for gene therapies. Based near Naples, Italy, and founded in 2020 as a spin-off from the Telethon Institute of Genetics and Medicine (TIGEM), the company leverages over 20 years of experience to support clients from discovery research through clinical trials. InnovAAVector offers services that include plasmid cloning, process development, technology transfer, and quality management. Their mission is to enhance and optimize AAV production processes, guiding clients from molecule development to clinical application while upholding the highest quality standards.